Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Chief Legal Officer | September 01, 2026 | September 03, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Adm, Leg & BD Off | February 24, 2021 | February 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-09-01 | Direct | 7,405 |
Reported balance
After 2026-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 7,405 · Balance 7,405 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of September 1, 2026.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2021 · Filed February 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,837 |
Ending reported balance
After 2021-02-25 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-24 · Tax withholding · Disposed 2,416 · Balance 33,865 Row 2 · 2021-02-25 · Sale · Disposed 646 · Balance 33,219 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91). F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2021-02-25 · Sale · Disposed 1,348 · Balance 31,871 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68). Row 4 · 2021-02-25 · Sale · Disposed 680 · Balance 31,191 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69). Row 5 · 2021-02-25 · Sale · Disposed 354 · Balance 30,837 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76). |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91).
F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68).
F5: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69).
F6: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2020 Filed Feb 26, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,416 | $239.23 | $577,979.68 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,866 Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 694 | $245.52 | $170,390.88 |
DisclosureSEC source: 0001209191-20-010546 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,282 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.52 (range $245.26 to $245.86). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 416 | $244.64 | $101,770.24 |
DisclosureSEC source: 0001209191-20-010546 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,976 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $244.64 (range $244.25 to $245.23). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 560 | $243.59 | $136,410.40 |
DisclosureSEC source: 0001209191-20-010546 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,392 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.59 (range $243.24 to $244.15). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,098 | $242.64 | $266,418.72 |
DisclosureSEC source: 0001209191-20-010546 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,952 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.64 (range $242.24 to $243.21). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 360 | $241.75 | $87,030.00 |
DisclosureSEC source: 0001209191-20-010546 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,050 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $241.75 (range $241.24 to $242.23). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,496 | $241.50 | $602,784.00 |
DisclosureSEC source: 0001209191-20-010546 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,410 Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,344 | $248.52 | $334,010.88 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,906 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $248.52 (range $248.23 to $248.93). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,499 | $247.62 | $618,802.38 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,250 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $247.62 (range $247.14 to $248.08). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,783 | $246.52 | $932,585.16 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,749 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $246.52 (range $246.14 to $247.11). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,232 | $245.62 | $1,530,703.84 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,532 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $245.62 (range $245.12 to $246.11). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,102 | $244.67 | $514,296.34 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,764 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $244.67 (range $243.94 to $244.93). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 922 | $243.42 | $224,433.24 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,866 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $243.42 (range $242.88 to $243.81). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 22:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 13,458 | $240.95 | $3,242,705.10 |
DisclosureSEC source: 0001209191-20-008882 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,788 Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,223 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-007505 · doc4.xml · derivative · entry 11 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,783 Underlying: Common Stock · 1,223 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,303 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-007505 · doc4.xml · derivative · entry 10 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,642 Underlying: Common Stock · 1,303 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 154 | $242.47 | $37,340.38 |
DisclosureSEC source: 0001209191-20-007505 · doc4.xml · nonDerivative · entry 9 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,246 F4 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $240.79 | $72,237.00 |
DisclosureSEC source: 0001209191-20-007505 · doc4.xml · nonDerivative · entry 8 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,400 F4 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F6 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $240.79 (range $240.51 to $241.05). Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 585 | $239.58 | $140,154.30 |
DisclosureSEC source: 0001209191-20-007505 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,700 F4 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F6 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $239.58 (range $239.17 to $240.11). Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,487 | $238.77 | $355,050.99 |
DisclosureSEC source: 0001209191-20-007505 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,285 F4 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F5 · price: Open market sales reported on this line occurred at a weighted average price of $238.77 (range $238.15 to $239.11). F6 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,223 | $155.57 | $190,262.11 |
DisclosureSEC source: 0001209191-20-007505 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,303 | $187.53 | $244,351.59 |
DisclosureSEC source: 0001209191-20-007505 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007505 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,246 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2021. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 8,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007505 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,923 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 02/24/2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 18,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007505 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,757 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · derivative · entry 11 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,320 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $233.03 | $93,212.00 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 9 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,553 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $233.03 (range $232.95 to $233.26). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,500 | $231.84 | $347,760.00 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 8 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,953 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $231.84 (range $231.58 to $232.44). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,350 | $231.20 | $312,120.00 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,453 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $231.20 (range $230.53 to $231.52). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 612 | $230.02 | $140,772.24 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,803 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.02 (range $229.48 to $230.47). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 574 | $229.07 | $131,486.18 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,415 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.07 (range $228.44 to $229.42). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,909 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · derivative · entry 10 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,945 Underlying: Common Stock · 3,909 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,344 | $231.21 | $310,746.24 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,659 Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,909 | $238.65 | $932,882.85 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,909 | $187.53 | $733,054.77 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-004809 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,854 Underlying: Common Stock · 1 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1 | $237.50 | $237.50 |
DisclosureSEC source: 0001209191-20-004809 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1 | $187.53 | $187.53 |
DisclosureSEC source: 0001209191-20-004809 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,125 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-20-003457 · doc4.xml · derivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 2,125 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/12/2016. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $228.99 | $68,697.00 |
DisclosureSEC source: 0001209191-20-003457 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $228.99 (range $228.79 to $229.27). Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $227.56 | $68,268.00 |
DisclosureSEC source: 0001209191-20-003457 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,303 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $227.56 (range $227.53 to $227.62). Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,225 | $226.42 | $277,364.50 |
DisclosureSEC source: 0001209191-20-003457 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,603 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $226.42 (range $226.06 to $227.01). Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $225.27 | $67,581.00 |
DisclosureSEC source: 0001209191-20-003457 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,828 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $225.27 (range $224.75 to $225.57). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,125 | $90.29 | $191,866.25 |
DisclosureSEC source: 0001209191-20-003457 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,250 | $0.00 Strike: $122.45 | $0.00 |
DisclosureSEC source: 0001209191-20-002501 · doc4.xml · derivative · entry 8 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,250 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 329 | $224.11 | $73,732.19 |
DisclosureSEC source: 0001209191-20-002501 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $224.11 (range $224.02 to $224.27). Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,063 | $223.60 | $237,686.80 |
DisclosureSEC source: 0001209191-20-002501 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,332 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $223.60 (range $223.19 to $223.99). Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 398 | $222.67 | $88,622.66 |
DisclosureSEC source: 0001209191-20-002501 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,395 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $222.67 (range $222.14 to $222.99). Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,599 | $221.49 | $354,162.51 |
DisclosureSEC source: 0001209191-20-002501 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,793 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $221.49 (range $221.00 to $221.82). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.